Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease.
暂无分享,去创建一个
[1] C. Peers,et al. Physiological roles for amyloid beta peptides. , 2006, The Journal of physiology.
[2] Ashley I. Bush,et al. Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.
[3] L. Villa-komaroff,et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.
[4] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[5] Y. Mimori,et al. Association Between Dementia and Midlife Risk Factors: the Radiation Effects Research Foundation Adult Health Study , 2003, Journal of the American Geriatrics Society.
[6] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[7] C. Masters,et al. The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease. , 1981, Brain : a journal of neurology.
[8] Kenjiro Ono,et al. Structure–neurotoxicity relationships of amyloid β-protein oligomers , 2009, Proceedings of the National Academy of Sciences.
[9] T. Suuronen,et al. Inflammation in Alzheimer's disease: Amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors , 2009, Progress in Neurobiology.
[10] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[11] Kayalvili Sanmugam. Depression is a Risk Factor for Alzheimer Disease- Review , 2015 .
[12] Miguel Ángel Martínez,et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. , 1997, American journal of human genetics.
[13] B. de Strooper,et al. Loss‐of‐function presenilin mutations in Alzheimer disease , 2007, EMBO reports.
[14] Karl Herrup,et al. The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.
[15] X. Chen,et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease , 2005 .
[16] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[17] George B. Benedek,et al. Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .
[18] F. Tarazi,et al. Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.
[19] Xiongwei Zhu,et al. Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.
[20] R. Nitrini,et al. Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls. , 2016, Journal of Alzheimer's disease : JAD.
[21] S. Lipton,et al. Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-d-aspartate receptors , 2012, Proceedings of the National Academy of Sciences.
[22] Meng Zhang,et al. A study on the association between infectious burden and Alzheimer's disease , 2015, European journal of neurology.
[23] E. Siemers,et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.
[24] M. Wolfe. Processive proteolysis by γ-secretase and the mechanism of Alzheimer’s disease , 2012, Biological chemistry.
[25] L. Donini,et al. Nutritional status determinants and cognition in the elderly. , 2007, Archives of gerontology and geriatrics.
[26] K. P. Kepp,et al. The Dependence of Amyloid-β Dynamics on Protein Force Fields and Water Models. , 2015, Chemphyschem : a European journal of chemical physics and physical chemistry.
[27] David M Holtzman,et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.
[28] A. Goate,et al. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.
[29] K. Moore,et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.
[30] I. Kohane,et al. Gene regulation and DNA damage in the ageing human brain , 2004, Nature.
[31] I. Slutsky,et al. Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses , 2009, Nature Neuroscience.
[32] O. Almkvist,et al. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.
[33] Kye Y. Kim,et al. Risk factors for Alzheimer's disease: an overview for clinical practitioners. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
[34] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[35] Mark A. Smith,et al. Alzheimer Disease and Oxidative Stress , 2002, Journal of biomedicine & biotechnology.
[36] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[37] Richard Mayeux,et al. Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.
[38] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[39] Richard Hollister,et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.
[40] Hilkka Soininen,et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.
[41] C. Glabe. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease , 2006, Neurobiology of Aging.
[42] Ottavio Arancio,et al. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? , 2012, The Biochemical journal.
[43] A. Palmeri,et al. Rodent models for Alzheimer’s disease drug discovery , 2015, Expert opinion on drug discovery.
[44] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[45] K. P. Kepp,et al. Bioinorganic chemistry of Alzheimer's disease. , 2012, Chemical reviews.
[46] P. Steiner,et al. Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein* , 2014, The Journal of Biological Chemistry.
[47] R. Nanga,et al. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity , 2010, Proceedings of the National Academy of Sciences.
[48] E. Siemers,et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[49] M. Tiwari,et al. β-Amyloid pathogenesis: Chemical properties versus cellular levels , 2016, Alzheimer's & Dementia.
[50] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.
[51] K. P. Kepp,et al. Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic Aβ Variants. , 2015, ACS chemical neuroscience.
[52] R. Castellani,et al. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.
[53] A. Hofman,et al. Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .
[54] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[55] L. Kiemeney,et al. Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.
[56] K. Yaffe,et al. The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.
[57] K. P. Kepp,et al. Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease , 2016, Journal of neurochemistry.
[58] W. Banks,et al. A Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory , 2010 .
[59] S. Hébert,et al. Differential contribution of the three Aph1 genes to γ-secretase activity in vivo , 2005 .
[60] J. Busciglio,et al. Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.
[61] K. Blennow,et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[62] L. Bäckman,et al. Multiple cognitive deficits during the transition to Alzheimer's disease , 2004, Journal of internal medicine.
[63] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[64] R. Kane,et al. Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity* , 2012, The Journal of Biological Chemistry.
[65] J. Quinn,et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.
[66] G. Schellenberg,et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.
[67] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[68] J. Gilthorpe,et al. Reactivated herpes simplex infection increases the risk of Alzheimer's disease , 2015, Alzheimer's & Dementia.
[69] F. Barkhof,et al. Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) , 2016 .
[70] Robert A. Dean,et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.
[71] D. Selkoe,et al. Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.
[72] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[73] Xi Chen,et al. Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .
[74] J. Galvin,et al. Distinguishing Alzheimer’s disease from other major forms of dementia , 2011, Expert review of neurotherapeutics.
[75] Charles D. Smith,et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.
[76] M. Matamales,et al. Modes of Aβ toxicity in Alzheimer’s disease , 2011, Cellular and Molecular Life Sciences.
[77] Ayyalusamy Ramamoorthy,et al. Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation. , 2012, Biophysical journal.
[78] K. Zou,et al. A Novel Function of Monomeric Amyloid β-Protein Serving as an Antioxidant Molecule against Metal-Induced Oxidative Damage , 2002, The Journal of Neuroscience.
[79] K. P. Kepp,et al. The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access , 2016, Neurobiology of Disease.
[80] C. Peers,et al. Physiological roles for amyloid β peptides , 2006 .
[81] R. Nitrini,et al. Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls. , 2016, Journal of Alzheimer's disease : JAD.
[82] Nick C Fox,et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.
[83] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[84] Ashley I. Bush,et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease , 2014, Neurobiology of Aging.
[85] Mark P Mattson,et al. Antiparallel β-sheet architecture in Iowa-mutant β-amyloid fibrils , 2012, Proceedings of the National Academy of Sciences.
[86] G. Eslick,et al. BACTERIAL INFECTION AND ALZHEIMER'S DISEASE: A META-ANALYSIS , 2014, Alzheimer's & Dementia.
[87] C. Peers,et al. The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons , 2003, The Journal of Neuroscience.
[88] Guy D. Eslick,et al. BACTERIAL INFECTION AND ALZHEIMER'S DISEASE: A META-ANALYSIS , 2014, Alzheimer's & Dementia.
[89] W. Rosenblum. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult , 2014, Neurobiology of Aging.
[90] A. Wimo,et al. The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.
[91] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[92] F. Fabris,et al. Risk factors for dementia of Alzheimer's type: a case-control, retrospective evaluation. , 2001, Archives of gerontology and geriatrics. Supplement.
[93] Wiesje M. van der Flier,et al. CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.
[94] Alyssa A. Gamaldo,et al. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis , 2014, BMC Public Health.
[95] Kasper P. Kepp,et al. A Model of Proteostatic Energy Cost and Its Use in Analysis of Proteome Trends and Sequence Evolution , 2014, PloS one.
[96] A Hofman,et al. Relation between smoking and risk of dementia and Alzheimer disease , 2007, Neurology.
[97] Rusha Shah. The role of nutrition and diet in Alzheimer disease: a systematic review. , 2013, Journal of the American Medical Directors Association.
[98] R. Lal,et al. Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .
[99] B. de Strooper,et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.
[100] N. Calcutt,et al. The pathological interaction between diabetes and presymptomatic Alzheimer's disease , 2009, Neurobiology of Aging.
[101] Hugo Vanderstichele,et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.
[102] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[103] D. Kirschner,et al. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.
[104] R. J. Kelleher,et al. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.
[105] Roger M. Nitsch,et al. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study , 2015, Alzheimer's & Dementia.
[106] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[107] Z. Janka,et al. Risk factors of cognitive decline in residential care in Hungary , 2007, International journal of geriatric psychiatry.
[108] Hai Lin,et al. Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[109] V. Papadopoulos,et al. Beta-Amyloid and Oxidative Stress Jointly Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory Impairment in the Rat Brain , 2005, Pharmacology.
[110] M. Tiwari,et al. Pathogenic properties of Alzheimer's β-amyloid identified from structure-property patient-phenotype correlations. , 2015, Dalton transactions.
[111] J. Brender,et al. Membrane disordering is not sufficient for membrane permeabilization by islet amyloid polypeptide: studies of IAPP(20-29) fragments. , 2013, Physical chemistry chemical physics : PCCP.
[112] K. Yaffe,et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.
[113] B. de Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.
[114] D. Selkoe,et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.
[115] K. Morgan,et al. Review: The genetics of Alzheimer's disease; putting flesh on the bones , 2014, Neuropathology and applied neurobiology.
[116] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[117] H. Lin,et al. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[118] Michael J Owen,et al. Alzheimer's disease genetics: current knowledge and future challenges , 2011, International journal of geriatric psychiatry.
[119] M. Woodward. Prevention of Alzheimer's Disease and Other Dementias , 2003 .
[120] J. Hardy,et al. A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.
[121] J. Karlawish. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease , 2011, Neurology.
[122] C. Dufouil,et al. Cardiovascular risk profile in women and dementia. , 2014, Journal of Alzheimer's Disease.
[123] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[124] L. Jungbauer,et al. Preparing synthetic Aβ in different aggregation states. , 2011, Methods in molecular biology.
[125] Ronald C Petersen,et al. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.
[126] D. Selkoe,et al. Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.
[127] D. Na,et al. Systematic review of health behavioral risks and cognitive health in older adults , 2009, International Psychogeriatrics.
[128] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[129] Nick C Fox,et al. Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.
[130] G. Sorrentino,et al. The dark sides of amyloid in Alzheimer's disease pathogenesis , 2014, FEBS letters.
[131] E. Rojas,et al. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[132] D. Drachman. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease , 2014, Alzheimer's & Dementia.
[133] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[134] H. Steinbusch,et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. , 2004, The American journal of pathology.
[135] D. Pollen,et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.
[136] T. Stijnen,et al. Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis , 2014, Alzheimer's & Dementia.
[137] P. Bosco,et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.
[138] P. Fraering,et al. Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified γ-Secretase Complexes , 2012, PloS one.
[139] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[140] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[141] A. Ramamoorthy,et al. Structural characterization and inhibition of toxic amyloid-β oligomeric intermediates. , 2013, Biophysical journal.
[142] J. Miklossy. Emerging roles of pathogens in Alzheimer disease , 2011, Expert Reviews in Molecular Medicine.
[143] R. Deane,et al. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. , 2007, Current Alzheimer research.
[144] B. Hyman,et al. The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide , 2010, PloS one.
[145] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[146] Sara Linse,et al. A facile method for expression and purification of the Alzheimer’s disease-associated amyloid β-peptide , 2009, The FEBS journal.
[147] Albert Hofman,et al. Alcohol consumption and risk of dementia: the Rotterdam Study , 2002, The Lancet.
[148] M. Tiwari,et al. Modeling the Aggregation Propensity and Toxicity of Amyloid-β Variants. , 2015, Journal of Alzheimer's disease : JAD.
[149] Lars Bertram,et al. Genome-wide association studies in Alzheimer's disease. , 2009, Human molecular genetics.
[150] H. Lashuel,et al. The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.
[151] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[152] D. Kirschner,et al. Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[153] Minna Rusanen,et al. Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia , 2015, Alzheimer's & Dementia.
[154] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[155] B. Dubois,et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.
[156] B. Strooper,et al. Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.
[157] J. Treanor,et al. Title beta-secretase cleavage of Alzheimer ' s amyloid precursor protein by the transmembrane aspartic protease , 2015 .